Compare HRTG & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | CGEM |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.5M | 904.7M |
| IPO Year | 2014 | 2020 |
| Metric | HRTG | CGEM |
|---|---|---|
| Price | $21.56 | $16.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $33.50 | $30.13 |
| AVG Volume (30 Days) | 467.6K | ★ 956.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $847,330,000.00 | N/A |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $5.20 |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $16.83 | $5.68 |
| 52 Week High | $31.98 | $16.74 |
| Indicator | HRTG | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 32.08 | 62.01 |
| Support Level | $20.98 | $11.92 |
| Resistance Level | $24.26 | N/A |
| Average True Range (ATR) | 1.07 | 1.03 |
| MACD | -0.17 | 0.08 |
| Stochastic Oscillator | 3.12 | 89.05 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.